A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol

NCT07487909 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Healthy

Interventions

DRUG: Treatment A- Fexofenadine HCl 60mg
DRUG: Treatment B- Naproxen sodium 220mg
DRUG: Treatment C- SJP-001 280mg
DRUG: Treatment D- Placebo-1
DRUG: Treatment E- Fexofenadine HCl 120mg
DRUG: Treatment F- Naproxen sodium 440mg
DRUG: Treatment G- SJP-001 560mg
DRUG: Treatment H- Placebo 2

Sponsor

Sen-Jam Pharmaceutical

Collaborators

[object Object]